Acquisitions and Other Transactions (Other Transactions) (Narrative) (Details) - USD ($) $ / shares in Units, $ in Millions			3 Months Ended		12 Months Ended
	Feb. 28, 2024	Nov. 07, 2022	Sep. 30, 2023	Mar. 31, 2023	Dec. 31, 2023	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2024	Jan. 03, 2023	Dec. 31, 2020	Dec. 20, 2019
Business Acquisition [Line Items]
Contingent consideration liability					$ 215.1	$ 215.1	$ 375.0	$ 199.7
Equity securities					49.3	49.3	42.6
Goodwill					9,867.1	9,867.1	10,425.8	12,113.7
Business Acquisition, Pro Forma Revenue							16,283.4
Business Acquisition, Pro Forma Net Income (Loss)					93.8		1,905.7
Prepaid Expense and Other Assets, Current					2,028.1	$ 2,028.1	1,811.2
Revenues					$ 15,426.9		16,262.7	17,886.3
In Process Research And Development, Fair value Measurement Input, Discount Rate		23.90%
Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Goodwill								$ (919.7)
Product Rights And Licenses
Business Acquisition [Line Items]
Finite-Lived Intangible Asset, Useful Life					10 years	10 years
Famy Life Sciences
Business Acquisition [Line Items]
Equity securities												$ 25.0
Gain (Loss) on Disposition of Stock in Subsidiary or Equity Method Investee					$ 18.9
Mapi Pharma Ltd. | Variable Interest Entity, Not Primary Beneficiary
Business Acquisition [Line Items]
Variable Interest Entity, Maximum Milestone Payments					90.0	$ 90.0
Variable Interest Entity, Financial or Other Support, Amount			$ 30.0
Equity Securities, FV-NI, Unrealized Gain (Loss)			$ 45.6
Other Assets					132.1	132.1	56.4
Gain (Loss) on Investments				$ 16.5	62.1
Prepaid Expense and Other Assets, Current					$ 52.5	$ 52.5	$ 42.5
Viatris Inc.
Business Acquisition [Line Items]
Noncontrolling Interest, Ownership Percentage by Noncontrolling Owners											13.50%
Viatris Inc. | Famy Life Sciences
Business Acquisition [Line Items]
Noncontrolling Interest, Ownership Percentage by Noncontrolling Owners								13.50%				13.50%
Maximum
Business Acquisition [Line Items]
Finite-Lived Intangible Asset, Useful Life					20 years	20 years
Minimum
Business Acquisition [Line Items]
Finite-Lived Intangible Asset, Useful Life					3 years	3 years
Oyster Point Pharma, Inc.
Business Acquisition [Line Items]
Acquisition purchase price				$ 427.4
Business Acquisition, Share Price				$ 11
Business Combination, Acquisition Related Costs					$ 22.8
Famy Life Sciences
Business Acquisition [Line Items]
Acquisition purchase price		$ 281.0
Oyster Point Pharma Acquisition
Business Acquisition [Line Items]
Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Inventory					29.3
Goodwill					6.7	$ 6.7				$ 5.9
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets					26.9	26.9				26.9
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Inventory					37.8	37.8				37.8
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Property, Plant, and Equipment					1.4	1.4				1.4
Business Combination Recognized Identifiable Assets Acquired and Liabilities Assumed, Deferred Tax Assets					16.9	16.9				17.7
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Other Noncurrent Assets					7.7	7.7				7.7
Current liabilities					431.4	431.4				431.4
Current liabilities					37.0	37.0				37.0
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Noncurrent Liabilities, Other					1.7	1.7				1.7
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net					392.7	392.7				392.7
Revenues						41.7
Net earnings attributable to Mylan N.V. ordinary shareholders						163.1
Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Goodwill						0.8
Oyster Point Pharma Acquisition | Product Rights And Licenses
Business Acquisition [Line Items]
Identified intangible assets					334.0	334.0				334.0
Famy Life Sciences Acquisition
Business Acquisition [Line Items]
Goodwill					89.2	89.2				89.3
Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Deferred Tax Liabilities						(0.1)
Current liabilities					379.2	379.2				379.3
Current liabilities					2.2	2.2				2.2
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net		325.0			325.0	325.0				325.0
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Deferred Tax Liabilities					52.0	52.0				52.1
Business Combination, Step Acquisition, Equity Interest in Acquiree, Fair Value		43.9
Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Goodwill						(0.1)
Famy Life Sciences Acquisition | In Process Research and Development [Member]
Business Acquisition [Line Items]
Identified intangible assets		$ 290.0			$ 290.0	$ 290.0				$ 290.0
Famy Life Sciences Acquisition | Scenario, Forecast | In Process Research and Development [Member]
Business Acquisition [Line Items]
Identified intangible assets									$ 120.0
Idorsia Pharmaceuticals Ltd. | Scenario, Forecast | Subsequent Event
Business Acquisition [Line Items]
Business Combination, Price of Acquisition, Expected	$ 350.0